Aaron P Rapoport

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes
    A P Rapoport
    University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Blood Cells Mol Dis 27:610-24. 2001
  2. pmc Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells
    Aaron P Rapoport
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 15:4499-507. 2009
  3. ncbi request reprint Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells
    A P Rapoport
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Bone Marrow Transplant 33:53-60. 2004
  4. ncbi request reprint Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma
    A P Rapoport
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Bone Marrow Transplant 34:883-90. 2004
  5. ncbi request reprint Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come
    A P Rapoport
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Bone Marrow Transplant 37:239-47. 2006
  6. ncbi request reprint Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
    Aaron P Rapoport
    University of Maryland Greenebaum Cancer Center and Center for Vaccine Development, 22 South Greene Street Baltimore, Maryland 21201, USA
    Nat Med 11:1230-7. 2005
  7. ncbi request reprint Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma
    Ashraf Badros
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    Clin Lymphoma Myeloma 7:210-6. 2006
  8. ncbi request reprint Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
    Ashraf Badros
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Cancer 110:1042-9. 2007
  9. ncbi request reprint Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Ashraf Z Badros
    Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 23:4089-99. 2005
  10. pmc Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
    Aaron P Rapoport
    University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA
    Blood 117:788-97. 2011

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes
    A P Rapoport
    University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Blood Cells Mol Dis 27:610-24. 2001
    ..Flavopiridol was also cytotoxic to seven other BL cell lines tested. These data suggest that flavopiridol may have therapeutic value in the treatment of Burkitt's lymphoma...
  2. pmc Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells
    Aaron P Rapoport
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 15:4499-507. 2009
    ..Here, we investigated the safety and kinetics of T-cell recovery after infusing ex-T at day +2 after transplant...
  3. ncbi request reprint Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells
    A P Rapoport
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Bone Marrow Transplant 33:53-60. 2004
    ..Autotransplantation followed by costimulated autologous T cells is feasible for patients with chronic phase CML, who lack allogeneic donors and can be associated with molecular remissions...
  4. ncbi request reprint Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma
    A P Rapoport
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Bone Marrow Transplant 34:883-90. 2004
    ..5 years, EFS=87%). There were no treatment-related deaths during or after the CC phase. Post-transplant CC is feasible and well tolerated. The impact of this approach on EFS should be evaluated in a larger, randomized study...
  5. ncbi request reprint Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come
    A P Rapoport
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Bone Marrow Transplant 37:239-47. 2006
    ....
  6. ncbi request reprint Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
    Aaron P Rapoport
    University of Maryland Greenebaum Cancer Center and Center for Vaccine Development, 22 South Greene Street Baltimore, Maryland 21201, USA
    Nat Med 11:1230-7. 2005
    ..05). In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the development of enhanced memory T-cell responses...
  7. ncbi request reprint Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma
    Ashraf Badros
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    Clin Lymphoma Myeloma 7:210-6. 2006
    ..In preclinical studies, bortezomib was shown to suppress tumor growth, sensitize malignant cells to apoptosis, and reverse chemotherapy resistance...
  8. ncbi request reprint Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
    Ashraf Badros
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Cancer 110:1042-9. 2007
    ..Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)...
  9. ncbi request reprint Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Ashraf Z Badros
    Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 23:4089-99. 2005
    ..Bcl-2 regulates the mitochondrial apoptosis pathway that promotes chemotherapy resistance. Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA...
  10. pmc Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
    Aaron P Rapoport
    University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA
    Blood 117:788-97. 2011
    ..This study was registered at www.clinicaltrials.gov as NCT00499577...
  11. doi request reprint Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies
    Bhavana Bhatnagar
    Blood and Marrow Transplantation Program, the Marlene and Stewart Greenebaum Cancer Center, Department of Medicine, University of Maryland, Baltimore, MD, 21201, USA
    Ann Hematol 93:653-60. 2014
    ..Further studies with TBI-MEL in standard risk transplant patients are warranted...
  12. ncbi request reprint Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy
    Merry Y Zhao
    Department of Pathology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Clin Cancer Res 15:1708-20. 2009
    ..This study aimed to identify and evaluate molecular targets for the development of a novel combination chemotherapy to treat refractory and recurrent diffuse large B-cell lymphoma (DLBCL)...
  13. doi request reprint Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease
    David L Brauer
    University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Transfusion 52:2432-5. 2012
    ..The drug has been widely used for treatment of multiple myeloma and myelodysplastic syndrome (MDS) associated with 5q-abnormality. The most common side effects are cytopenias, infections, and deep venous thrombosis...
  14. ncbi request reprint Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53
    Asit K Nandi
    Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Biochem Biophys Res Commun 358:181-8. 2007
    ..Together, our studies provide a plausible explanation for the role of PBK augmenting tumor cell growth following transient appearance in different types of progenitor cells in vivo as reported...
  15. doi request reprint c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas
    Fang Hu
    Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Leuk Res 37:447-54. 2013
    ..In conclusion, a c-Myc-E2F1-PBK signaling pathway operates in high-grade lymphomas and may provide a useful target for novel antineoplastic therapeutics...
  16. ncbi request reprint Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide
    Javier BolaƱos-Meade
    University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Room S9D07, Baltimore, MD 21201, USA
    Leuk Res 27:313-21. 2003
    ..However, patients of age equal to 60 years and those with poor-risk disease features still have poor CR and DFS, despite the addition of ATRA...
  17. ncbi request reprint Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients
    Naoko Takebe
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Clin Cancer Res 10:8301-8. 2004
    ..On the basis of our preclinical studies, we designed a clinical study to test our hypothesis that MMF has antimyeloma activity...
  18. ncbi request reprint Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literature
    Karl M Kasamon
    Department of Hematology, Greenebaum Cancer Center, University of Maryland, Baltimore 21201, USA
    Haematologica 90:ECR17. 2005
    ..The case is discussed in the framework of the existing literature and derives clinical practice recommendations for this rare but clinically devastating entity...
  19. ncbi request reprint Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF
    Asit K Nandi
    University of Maryland School of Medicine, Greenebaum Cancer Center, 655 W Baltimore Street, Baltimore, MD 21201, USA
    Leuk Res 30:437-47. 2006
    ..These findings may provide insight into the mechanisms that upregulate PBK expression in proliferative hematologic malignancies and down regulate its expression following growth arrest of leukemic cells...
  20. ncbi request reprint Detection of CD4(+) T-cell antibodies in a patient with idiopathic CD4 T lymphocytopenia and cryptococcal meningitis
    Rachel B Salit
    Department of Internal Medicine, The University of Maryland Medical Center, Baltimore, MD 21201, USA
    Br J Haematol 139:133-7. 2007
    ..61%) than the CD4(+) T cells of normal donors (3.94 +/- 1.77%). The reasons behind the development of these autoantibodies are explored...
  21. ncbi request reprint Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study
    Francis K Buadi
    Department of Medicine Division of Hematology Oncology Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Am J Hematol 82:208-14. 2007
    ..This study confirms the ability to treat a significant proportion of PTLD patients with chemotherapy or surgical resection (depending on presentation), without sacrificing graft function in those receiving chemotherapy...
  22. ncbi request reprint Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency
    Megan Dunnigan
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Dig Dis Sci 52:830-4. 2007
  23. ncbi request reprint Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A
    Clarence Sarkodee-Adoo
    Division of Hematology and Oncology, University of Maryland School of Medicine, Baltimore, USA
    Transfusion 43:78-84. 2003
    ..The optimal treatment of BMT-associated TMA is also not known...
  24. ncbi request reprint Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma
    Saranya Chumsri
    Leuk Lymphoma 48:616-8. 2007

Research Grants3

  1. Immune responses to T-cell expansion + PCV immunization
    Aaron Rapoport; Fiscal Year: 2005
    ..abstract_text> ..
  2. Immunotherapy after ASCT for MM Using hTERT Vaccination + Vaccine-primed T cells
    Aaron Rapoport; Fiscal Year: 2007
    ..AIM 2: To assay for development of cellular immune responses to the hTERT multi-peptide vaccine in the cohort of HLA A2+ patients who receive the combination of the multi-peptide vaccine and the vaccine-primed and costimulated T-cells. ..